The efficacy of early urotherapy for severe intolerable nocturnal enuresis before the age of 5 years: A prospective randomized trial.
- 1Department of Urology, Kasr Alainy Hospitals, Faculty of Medicine, Cairo University, Egypt.
- 2Department of Pediatrics, Aboelresh Hospital, Faculty of Medicine, Cairo University, Egypt.
- 3Department of Urology, Faculty of Medicine, Fayoum University, Egypt.
Abstract
Introduction
Assessment of the efficacy of early urotherapy for severe intolerable NE before the age of 5 years was the main objective.Material and methods
A total of 120 children, aged between 4 and 4.5 years, with intolerable NE (bedwetting ≥5 nights/ week) were included in our study. They were randomized into group A (early urotherapy regularly until age 5.5 years) and group B (deferred urotherapy started at age 5 years for 6 months). Only 107 (54 in group A, 53 in group B) were interviewed twice, at the age of 5 and 5.5 years, to determine treatment response, categorized as complete response (100% reduction), ≥90%, 50-89%, or <50% reduction in bedwetting during the preceding month. Parental adherence to urotherapy was evaluated using a structured 7-day diary and adherence checklist. In addition, their distress was evaluated and followed up using general health questionnaire-12 (GHQ-12) score.Results
Complete response through the last month was significantly higher in group A than group B at 5-year-old or 5.5-year-old visits (12 vs 6, 25 vs 10 children, respectively, p <0.05). Also, <50% reduction of bedwetting was significantly higher in group B than in group A in both visits (32 vs 27 and 23 vs 9 children, respectively, p <0.05). Both groups showed comparable levels of adherence to their protocol. CHQ-12 scores were significantly lower in group A than in B at the first visit, while no difference was observed at the second visit.Conclusions
Early urotherapy in children with intolerable nocturnal enuresis could enhance rapid recovery and reduce psychological distress.
Related
- Efficacy of Kinesio tape for central facial paralysis : A prospective, randomized sham-controlled, single-blinded clinical trial
- Comparison of analgesic efficacy and safety between liposomal bupivacaine and ropivacaine for paravertebral block in patients undergoing thoracoscopic lung tumor surgery: a prospective double-blind randomized controlled trial
- Efficacy and safety of trans-fornix conjunctival retrobulbar block in a prospective randomized controlled trial
- Evaluation of the Efficacy and Safety of Combination Therapy of Vamha and Myrha in the Management of PMOS: An Open-Label, Randomized, Multicentre, Comparative, Prospective Clinical Study
- Efficacy and Safety of 1.5‐ and 3.0‐mm High‐Intensity Focused Ultrasound for Eyebrow Lifting in Korean Adults: A Prospective Randomized Split‐Face Study
BibTeX
@article{rammah2026efficacy,
title = {{The efficacy of early urotherapy for severe intolerable nocturnal enuresis before the age of 5 years: A prospective randomized trial.}},
author = {Ahmed M Rammah and Mohamed Abdelghani and Shrouk M Abdalla and Ahmed Y Abdelaziz and Ahmed Sharawy and Mohamed Kishk and Mohamed Salah and Ahmed H Abozamel and Hesham Torad and Mahmoud S ElAdawy and Hossam Skaker and Hesham Ibrahim},
journal = {Central European journal of urology},
year = {2026},
month = jul,
doi = {10.5173/ceju.2025.0332},
url = {https://europepmc.org/article/MED/42903941},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - The efficacy of early urotherapy for severe intolerable nocturnal enuresis before the age of 5 years: A prospective randomized trial.
AU - Ahmed M Rammah
AU - Mohamed Abdelghani
AU - Shrouk M Abdalla
AU - Ahmed Y Abdelaziz
AU - Ahmed Sharawy
AU - Mohamed Kishk
AU - Mohamed Salah
AU - Ahmed H Abozamel
AU - Hesham Torad
AU - Mahmoud S ElAdawy
AU - Hossam Skaker
AU - Hesham Ibrahim
PY - 2026
DA - 2026/07/17
JO - Central European journal of urology
DO - 10.5173/ceju.2025.0332
UR - https://europepmc.org/article/MED/42903941
AB - Introduction Assessment of the efficacy of early urotherapy for severe intolerable NE before the age of 5 years was the main objective.Material and methods A total of 120 children, aged between 4 and 4.5 years, with intolerable NE (bedwetting ≥5 nights/ week) were included in our study. They were randomized into group A (early urotherapy regularly until age 5.5 years) and group B (deferred urotherapy started at age 5 years for 6 months). Only 107 (54 in group A, 53 in group B) were interviewed twice, at the age of 5 and 5.5 years, to determine treatment response, categorized as complete response (100% reduction), ≥90%, 50-89%, or <50% reduction in bedwetting during the preceding month. Parental adherence to urotherapy was evaluated using a structured 7-day diary and adherence checklist. In addition, their distress was evaluated and followed up using general health questionnaire-12 (GHQ-12) score.Results Complete response through the last month was significantly higher in group A than group B at 5-year-old or 5.5-year-old visits (12 vs 6, 25 vs 10 children, respectively, p <0.05). Also, <50% reduction of bedwetting was significantly higher in group B than in group A in both visits (32 vs 27 and 23 vs 9 children, respectively, p <0.05). Both groups showed comparable levels of adherence to their protocol. CHQ-12 scores were significantly lower in group A than in B at the first visit, while no difference was observed at the second visit.Conclusions Early urotherapy in children with intolerable nocturnal enuresis could enhance rapid recovery and reduce psychological distress.
SN - 2080-4806
SN - 2080-4873
ER -